Ideally, a prospective randomized study on the Brazilian population, comparing anti-EGFR TKI for EGFR-mutated advanced NSCLC patients with platinum-doublet chemotherapy for patients who do not undergo the molecular test, should be conducted. This evidence concerns the gene EGFR and non-small cell lung carcinoma.